Physician profile
Christopher N Bazal
NPI 1639260037
$16,957.98
in general payments reported to CMS, 2019-2025
60 companies · $2,793 in 2025
The $2,793 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,588 · 2020: $1,290 · 2021: $2,270 · 2022: $2,666 · 2023: $2,783 · 2024: $2,570 · 2025: $2,793.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,999 · Education: $146.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,998.76 |
| Education | $146.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,234.76 | 2019-2025 | Vraylar, Linzess, Viberzi |
| Glaxosmithkline, LLC. | $1,974.17 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $1,488.86 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $1,199.16 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,032.80 | 2019-2025 | Airsupra, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,024.23 | 2019-2025 | Jardiance, Ofev |
| Amgen INC. | $918.96 | 2019-2025 | Repatha, Evenity, Otezla |
| Dexcom, INC. | $851.53 | 2022-2025 | Dexcom G6 Transmitter |
| Otsuka America Pharmaceutical, INC. | $606.37 | 2020-2025 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $539.70 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $525.46 | 2019-2024 | Gardasil 9, Vaxneuvance, Rotateq |
| Lilly USA, LLC | $457.78 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Allergan, INC. | $298.75 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $276.90 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $266.28 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
Show all 60 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Bazal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.